BlackRock’s Juno Therapeutics, Inc. JUNO Stock Holding History

BlackRock’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,834,370	Closed	-$221M	–	5084
2017 Q4	$221M	Buy	4,834,370 +299,586	+7%	+$14.9M	0.01%	1293
2017 Q3	$203M	Buy	4,534,784 +240,488	+6%	+$8.2M	0.01%	1333
2017 Q2	$128M	Buy	4,294,296 +110,503	+3%	+$2.73M	0.01%	1625
2017 Q1	$92.8M	Buy	4,183,793 +4,170,511	+31,400%	+$89.5M	0.01%	1826
2016 Q4	$250K	Sell	13,282 -251	-2%	-$6.14K	﹤0.01%	2000
2016 Q3	$406K	Buy	13,533 +3,907	+41%	+$122K	﹤0.01%	1825
2016 Q2	$370K	Buy	9,626 +7,999	+492%	+$332K	﹤0.01%	1789
2016 Q1	$62K	Buy	1,627 +580	+55%	+$20.2K	﹤0.01%	2251
2015 Q4	$46K	Sell	1,047 -953	-48%	-$47.3K	﹤0.01%	2115
2015 Q3	$81K	Hold	2,000	–	–	﹤0.01%	1779
2015 Q2	$106K	Buy	2,000 +1,806	+931%	+$95.9K	﹤0.01%	1793
2015 Q1	$12K	Buy	+194	New	+$9.41K	﹤0.01%	2654

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

BlackRock's JUNO Position: Q1 2018 in Review

BlackRock sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 4,834,370 shares — an estimated $221M sold.

BlackRock first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $221M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

BlackRock reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
BlackRock sold 4,834,370 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $221M.
BlackRock first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
BlackRock's Juno Therapeutics, Inc. position peaked at $221M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on BlackRock's 13F filing for Q1 2018, filed 9 May 2018.